<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440778</url>
  </required_header>
  <id_info>
    <org_study_id>EASY-MI</org_study_id>
    <nct_id>NCT00440778</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI</brief_title>
  <acronym>EASY-MI</acronym>
  <official_title>A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute Myocardial Infarction: The EASY-MI Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quebec Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESES&#xD;
&#xD;
        1. Bolus administration of total abciximab dose provides superior maximal and mean platelet&#xD;
           aggregation inhibition (PAI) compared with standard bolus (0.25 mg/kg) administration.&#xD;
&#xD;
        2. Total dose of abciximab can be given as a single bolus and is more effective than bolus&#xD;
           (0.25 mg/kg) + 12 hrs infusion in terms of acute and mid-term angiographic and clinical&#xD;
           results.&#xD;
&#xD;
        3. Intracoronary (ic) abciximab administration is more effective than intravenous (iv)&#xD;
           route of administration in terms of acute and mid-term angiographic and clinical&#xD;
           results.&#xD;
&#xD;
        4. There is a relationship between PAI and angiographic perfusion scores.&#xD;
&#xD;
        5. Routine use of sirolimus-eluting stents (Cypher, Cordis) in primary-PCI is associated&#xD;
           with a low rate of target vessel revascularization and complications.&#xD;
&#xD;
        6. Cardiac MRI early and late after primary-PCI provides detailed information on myocardial&#xD;
           injury and irreversible necrosis, which are correlated with angiographic perfusion&#xD;
           scores.&#xD;
&#xD;
        7. After uncomplicated trans-radial PCI, patients can be retransferred early to their&#xD;
           referring center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES AND END-POINTS The objectives of the present study are to assess the benefits and&#xD;
      safety of 1) a single bolus of abciximab (100% dose) compared with the standard bolus (ca 80%&#xD;
      of the total dose) + 12h infusion (ca 20% of the total dose), and 2) intracoronary abciximab&#xD;
      bolus administration compared with intravenous route of abciximab administration in primary&#xD;
      PCI.&#xD;
&#xD;
      The primary PLATELETS end-points are the percentage of patients with ≥ 95% platelet&#xD;
      aggregation inhibition 10 minutes after abciximab bolus (MAX) and the mean platelet&#xD;
      aggregation inhibition 10 minutes after abciximab bolus (MEAN).&#xD;
&#xD;
      The secondary CLINICAL end-points of the study are:&#xD;
&#xD;
        -  The composite of death, stroke, repeat myocardial infarction, urgent target vessel&#xD;
           revascularization and major bleedings at 30 days following primary PCI.&#xD;
&#xD;
        -  The composite of cardiovascular death, repeat myocardial infarction and repeat target&#xD;
           vessel revascularization at 6-months follow-up.&#xD;
&#xD;
      The secondary ANGIOGRAPHIC end-points of the study are:&#xD;
&#xD;
        -  The proportion of patients having myocardial blush grade 2-3 and TIMI 3 score at the end&#xD;
           of PCI in the culprit vessel.&#xD;
&#xD;
        -  The restenosis rate (diameter stenosis ≥ 50%) and late loss in the culprit vessel at&#xD;
           6-months follow-up.&#xD;
&#xD;
      Other exploratory end-points are the feasibility and safety of early transfer to the&#xD;
      referring hospital after uncomplicated primary PCI, the cardiac MRI measurements and platelet&#xD;
      aggregation inhibition at 6h post-PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with at least 95% platelet aggregation inhibition, and mean platelet aggregation inhibition.</measure>
    <time_frame>10 min after bolus of abciximab</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of death, stroke, repeat MI, urgent target vessel revascularization and major bleedings at 30 days following primary PCI.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death, repeat MI and repeat target vessel revascularization at 6-month follow-up.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having myocardial blush grade 2-3 and TIMI 3 score at the end of PCI in the culprit vessel.</measure>
    <time_frame>At end of PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate (diameter stenosis equal or higher than 50%) and late loss in the culprit vessel at 6-month follow-up.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory end-points: feasibility and safety of early transfer to the referring hospital after uncomplicated primary PCI, cardiac MRI measurements and platelet aggregation inhibition at 6hr post-PCI.</measure>
    <time_frame>At 6hr post-PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Gr 1 - intracoronary + infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gr 2 - intracoronary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100% abciximab bolus dose 0.3 mg/kg ic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gr 3 - intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gr 4 - intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100% abciximab bolus dose 0.3 mg/kg iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <description>100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion</description>
    <arm_group_label>Gr 1 - intracoronary + infusion</arm_group_label>
    <arm_group_label>Gr 2 - intracoronary</arm_group_label>
    <arm_group_label>Gr 3 - intravenous</arm_group_label>
    <arm_group_label>Gr 4 - intravenous</arm_group_label>
    <other_name>Abciximab (ReoPro)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with acute myocardial infarction eligible for primary PCI within 6 h of&#xD;
             symptoms: patient must have prolonged, continuous (lasting at least 20 minutes) signs&#xD;
             and symptoms of ischemia not eliminated with nitrates and onset within 6 h of&#xD;
             randomization, and one of the following:&#xD;
&#xD;
               -  ST-segment elevation ≥ 2 mm in 2 or more contiguous precordial ECG leads&#xD;
                  (anterior infarction)&#xD;
&#xD;
               -  ST-segment depression ≥ 2 mm in V1, V2 or V2, V3 with reciprocal 1 mm&#xD;
                  ST-elevation in II, augmented unipolar foot (left leg) lead (AVF), and V6 (true&#xD;
                  posterior infarction)&#xD;
&#xD;
               -  ST-segment elevation ≥ 1 mm in 2 or more contiguous limb ECG leads (other&#xD;
                  infarction)&#xD;
&#xD;
               -  New or presumably new left bundle branch block (LBBB)&#xD;
&#xD;
          -  Patient must be &gt; 18 years of age.&#xD;
&#xD;
          -  Patient and treating interventional cardiologist agree for randomization.&#xD;
&#xD;
          -  Patient will be informed of the randomization process and will sign an informed&#xD;
             consent.&#xD;
&#xD;
          -  Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery&#xD;
             approach.&#xD;
&#xD;
          -  The culprit lesion can be identified on a native coronary vessel, which is suitable&#xD;
             for primary PCI with stent implantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has received thrombolytic therapy (within the last 4 weeks) and is referred&#xD;
             for rescue PCI&#xD;
&#xD;
          -  Concurrent participation in other investigational study&#xD;
&#xD;
          -  Femoral sheath (artery)&#xD;
&#xD;
          -  Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for at&#xD;
             least 12 months&#xD;
&#xD;
          -  Any significant blood dyscrasia, diathesis or INR &gt; 2.0&#xD;
&#xD;
          -  Any clinical contraindication to abciximab (ReoPro®) administration i.e. known&#xD;
             structural intracranial lesion, thrombocytopenia &lt; 100,000, active or recent bleeding&#xD;
             or hemoglobin level known &lt; 10 g/dl.&#xD;
&#xD;
          -  Any glycoprotein IIb-IIIa inhibitors use in the previous 30 days&#xD;
&#xD;
          -  Uncontrolled high blood pressure i.e. systolic blood pressure ≥ 180 mmHg and/or&#xD;
             diastolic blood pressure ≥ 100 mmHg.&#xD;
&#xD;
          -  Life expectancy less than 6 months owing to non-cardiac cause&#xD;
&#xD;
          -  Infarction caused by in-stent thrombosis or restenosis&#xD;
&#xD;
          -  Cardiogenic shock evident before randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier F Bertrand, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval Hospital Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <last_update_submitted>November 23, 2011</last_update_submitted>
  <last_update_submitted_qc>November 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Olivier F. Bertrand</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Coronary artery stenting</keyword>
  <keyword>Trans-radial</keyword>
  <keyword>Intracoronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

